Upregulation of sICAM-1 and sVCAM-1 Levels in the Cerebrospinal Fluid of Patients with Schizophrenia Spectrum Disorders
Authors:
- Sophie MeixensbergerSMSophie Meixensberger
- Hanna KuziorHKHanna Kuzior
- Bernd L. FiebichBFBernd L. Fiebich
- Patrick SüßPSPatrick Süß
- Kimon RungeKRKimon Runge
- Benjamin BergerBBBenjamin Berger
- Kathrin NickelKNKathrin Nickel
- Dominik DenzelDDDominik Denzel
- Miriam A. SchieleMSMiriam A. Schiele
- Maike MichelMMMaike Michel
- Simon MaierSMSimon Maier
- Karl BechterKBKarl Bechter
Open Access
- 22 June 2021
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 11 (7) , 1134
Abstract
Immunological explanatory approaches are becoming increasingly important in schizophrenia research. In this context, the function of the blood-brain barrier (BBB) and the blood-cerebrospinal fluid (CSF) barrier (BCSFB) plays an essential role. Different adhesion molecules, such as intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1), are key elements in sustaining the integrity of the BBB and BCSFB. The objectives of this study were to (1) compare the levels of different cell adhesion molecules in the CSF of patients with schizophrenia spectrum disorders to those of patients with unipolar depression and (2) analyze their association with the established markers of the BBB/BCSFB function (CSF total protein and albumin quotient (AQ)). Therefore, a total of 40 patients with schizophrenia spectrum disorder and 39 age- and sex-matched control patients with unipolar depression were analyzed. The levels of soluble ICAM-1 (s-ICAM-1), soluble VCAM-1 (s-VCAM-1), and plasminogen activator inhibitor 1 (PAI-1) in the CSF were measured using a magnetic bead multiplexing immunoassay. The levels of sICAM-1 (p < 0.001), sVCAM-1 (p < 0.001), and PAI-1 (p < 0.001) in the CSF were significantly higher in patients with schizophrenia spectrum disorder than in patients with unipolar depression. In addition, a significant correlation of sVCAM-1 levels with total protein concentrations (r = 0.454, p = 0.003) and AQ levels (r = 0.512, p = 0.001) in patients with schizophrenia spectrum disorders was observed. The results revealed that sICAM-1 and sVCAM-1 levels in the CSF were higher in patients with schizophrenia spectrum disorder than in those with depression. These circulating signaling molecules may indicate endothelial dysfunction causing impaired BBB/BCSFB function in patients with schizophrenia spectrum disorders. Consistent with this view, a highly significant correlation of sVCAM-1 with CSF protein and AQs was detected. Upregulation of these cell adhesion molecules might be indicative of a proinflammatory immune response underlying the BBB/BCSFB disturbance in a subgroup of patients with schizophrenia spectrum disorders. The significance of the study is limited by its retrospective research design and by the absence of a healthy control group. The assay used was not previously established for the measurement of CSF. Further translational and controlled studies of the role of different cell adhesion molecules in schizophrenia are needed.Keywords
All Related Versions
Funding Information
- N.A. (The article processing charge was funded by the Baden-Wuerttemberg Ministry of Science, Research and Art and the University of Freiburg in the funding programme Open Access Publishing.)
This publication has 36 references indexed in Scilit:
- Cerebrospinal fluid, antineuronal autoantibody, EEG, and MRI findings from 992 patients with schizophreniform and affective psychosisTranslational Psychiatry, 2020
- Autoimmune psychosis: an international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune originThe Lancet Psychiatry, 2020
- The Role of Intercellular Adhesion Molecule-1 in the Pathogenesis of Psychiatric DisordersFrontiers in Pharmacology, 2019
- The blood–brain barrier in psychosisThe Lancet Psychiatry, 2018
- Abnormal levels of vascular endothelial biomarkers in schizophreniaEuropean Archives of Psychiatry and Clinical Neuroscience, 2017
- Neurovascular Unit Dysfunction and Blood–Brain Barrier Hyperpermeability Contribute to Schizophrenia Neurobiology: A Theoretical Integration of Clinical and Experimental EvidenceFrontiers in Psychiatry, 2017
- Role of sICAM-1 and sVCAM-1 as biomarkers in early and late stages of schizophreniaJournal of Psychiatric Research, 2016
- Immunological findings in psychotic syndromes: a tertiary care hospital's CSF sample of 180 patientsFrontiers in Human Neuroscience, 2015
- Neurovascular unit dysfunction with blood-brain barrier hyperpermeability contributes to major depressive disorder: a review of clinical and experimental evidenceJournal of Neuroinflammation, 2013
- Updating the mild encephalitis hypothesis of schizophreniaProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2013